CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CVHLC77fs (c.230del)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLL118P (c.353T>C)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLQ96_P97delinsH (c.288_290del)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLG144fs (c.429_439del)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLG114R (c.340G>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsSensitivity/ResponseCancerDasatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 H396PPredictiveSupportsSensitivity/ResponseCancerDasatinibDeguchi et al., 2008
DSPOPM117VFunctionalSupportsLoss of FunctionZhang et al., 2015
BNUP214::ABL1FusionPrognosticSupportsBetter OutcomeB-lymphoblastic Leukemia/lymphomaden Boer et al., 2021
CSFPQ::ABL1FusionOncogenicSupportsOncogenicityB-lymphoblastic Leukemia/lymphomaDuhoux et al., 2011
CSFPQ::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaImatinib,DasatinibBiloglav et al., 2020
CSFPQ::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeSheng et al., 2017
CRCSD1::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaDasatinibMustjoki et al., 2009
CRCSD1::ABL1FusionPredictiveSupportsReduced SensitivityB-lymphoblastic Leukemia/lymphomaDasatinibInokuchi et al., 2011
CRCSD1::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphomaDe Braekeleer et al., 2013
CRCSD1::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaDasatinibFrech et al., 2017
CETV6::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaImatinibMankuzhy et al., 2019
CSNX2::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeImamura et al., 2016
CSNX2::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2014
CRCSD1::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaPonatinibCollette et al., 2015
DSPOPR121QFunctionalSupportsLoss of FunctionZhang et al., 2015
DSPOPM117IFunctionalSupportsLoss of FunctionZhang et al., 2015
CEGFRA767_V769dupASVPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibFang et al., 2019
CEGFRD770_N771insGPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibFang et al., 2019
CEGFRS768_D770dupPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibFang et al., 2019
DATRXDeletionPredictiveSupportsSensitivity/ResponseCancerCisplatin,FluorouracilConte et al., 2012
BCDKN1Ars1059234PredisposingSupportsPredispositionRetinoblastomaCarvalho et al., 2013
DTP53A161TFunctionalSupportsLoss of FunctionPekova et al., 2011
CMEF2D::CSF1RFusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeImatinibTanasi et al., 2019
CTBL1XR1::CSF1RFusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
DEZH2Y646FunctionalSupportsGain of FunctionSneeringer et al., 2010
DPTENC136RFunctionalSupportsLoss of FunctionHe et al., 2013
DEZH2Y646FFunctionalSupportsGain of FunctionYap et al., 2011
DEZH2Y646NFunctionalSupportsGain of FunctionYap et al., 2011
DEZH2Y646FFunctionalSupportsLoss of FunctionYap et al., 2011
DEZH2Y646NFunctionalSupportsLoss of FunctionYap et al., 2011
DEZH2Y646HFunctionalSupportsGain of FunctionYap et al., 2011
DEZH2Y646SFunctionalSupportsGain of FunctionYap et al., 2011
BH3-3AG34RDiagnosticSupportsPositiveDiffuse Glioma, H3 G34 MutantWu et al., 2012
DBRAFG463EOncogenicSupportsOncogenicityCancerWan et al., 2004
CVHLL158P (c.473T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
CVHLR167Q (c.500G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
CVHLN78S (c.233A>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
CVHLR161* (c.481C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
CVHLR113* (c.337C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
BH3C2K27MDiagnosticSupportsPositiveDiffuse Midline Glioma, H3 K27M-mutantWu et al., 2012
DNFE2L2G31AFunctionalSupportsGain of FunctionKim et al., 2016
CLMNA::NTRK1FusionPredictiveSupportsSensitivity/ResponseSolid TumorLarotrectinibHong et al., 2019
AEZH2Activating MutationPredictiveSupportsSensitivity/ResponseFollicular LymphomaTazemetostatMorschhauser et al., 2020
CBRAFT599dupPredictiveSupportsSensitivity/ResponseGangliogliomaTrametinib,DabrafenibMiller et al., 2021
Page 59 of 96
PreviousNext